Scholars Central

Research articlePublished 2012

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Authors: Arzu Didem Yalcin, Atil Bisgin

Journal of Allergy & Therapy

Volume 3 · Issue 2 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: The primary use of omalizumab (trade name Xolair) is for patients with severe, persistent and allergic asthma. Our aim was to evaluate the therapeutic efficacy of omalizumab as a treatment modality in patients with different allergic conditions. Methods: There were eleven patients, whom followed-up with omalizumab therapy in the Immunology - Allergy Clinic, were evaluated by the clinical findings of nasal polyposis, anaphylaxis history, drug allergy, latex allergy, food allergy, autoimmune urticaria, allergic rhino-conjunctivitis, atopic dermatitis, angioedema and venom allergy. Results: The patients, who had severe persistent asthma for periods ranging from 3 to 8 years, were enrolled in the study. Omalizumab was chosen as a potential new systemic therapy for the patients due to the clinical indication. Clinical symptoms of the all patients with severe persistent asthma were decreased. And in addition, asthma control test and pulmonary function tests were improved up. A severe anaphylactic reaction is prevented in a patient with 48 bee stings. Conclusion: This clinical follow-up of omalizumab treated patients with severe persistent asthma and many different allergic conditions, suggests omalizumab is an effective therapy for asthma and different allergic conditions.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Allergy & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Allergy & Therapy
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Arzu Didem Yalcin”
  • BylineArticles whose byline prints “Atil Bisgin”